Changes in plasma glucose, insulin, glucagon, catecholamine, and glycogen contents in tissues during development of alloxan diabetes mellitus in rats

Biochemical and Molecular Medicine

Volumn 62, Issue 1, 1997, Pages 70-75

  Oi, Kazuteru ^a,b   Komori, Hiromi ^b   Kajinuma, Hiroshi ^b  

^a TOHO UNIVERSITY   (Japan)

^b TOHO UNIVERSITY OHASHI MEDICAL CENTER   (Japan)

Author keywords

Alloxan diabetes; Catecholamine; Glucagon; Glycogen in tissue; Insulin

Indexed keywords

CATECHOLAMINE; GLUCAGON; GLYCOGEN; INSULIN;

ADIPOSE TISSUE; ALLOXAN DIABETES MELLITUS; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; DIET RESTRICTION; GLUCOSE BLOOD LEVEL; HORMONE RESPONSE; IMMUNOREACTIVITY; KIDNEY CORTEX; METABOLIC DISORDER; MUSCLE DEVELOPMENT; MUSCLE TISSUE; NONHUMAN; RAT;

ANIMALIA;

EID: 0031258709     PISSN: 10773150     EISSN: None     Source Type: Journal    
DOI: 10.1006/bmme.1997.2622     Document Type: Article

References (13)

1. 1. Oi K, Shimoda Y, Komori H, Maruyama M, Shimoda K, Toyoda M. Anabolic response in the renal cortex of diabetic rats: Synthetase of glycogen. J Med Soc Toho 37:42-47, 1990.
2. 2. Oi K, Ihara H, Shimoda Y, Toyoda M. Determination of low content glycogen in kidney cortex of diabetes rats. J Anal BioSci 13:38-40, 1990.
3. 3. Dunn JS, Sheehan HL, McLetchie GB. Necrosis of the islets of Langerhans produced experimentally. Lancet 1:484-487, 1943.
4. 4. Houssay, BA, Orias O, Sara I. The mechanism of action of alloxan on blood sugar. Science 102:197-200, 1945.
5. 5. Lukens FDW. Alloxan diabetes. Physiol Rev 28:304-330, 1948.
6. 6. Wrenshall GA, Colllins-Williams J, Best CH. Initial changes in the blood sugar of the fasted anesthetized dog after alloxan. Am J Physiol 160:228-246, 1950.
7. 7. Kosaka K. Studies on the mechanism of alloxan initial hyperglycemia: The role of pituitary and adrenal glands in connection with the effect of alloxan on the blood sugar. Tohoku J Exp Med 59:379-391, 1954.
8. 8. Kikuchi M, Miki E, Kuzuya T. Changes in plasma immunoreactive insulin level during the development of alloxan diabetes in dogs. J Jpn Diabetes Soc 11:351-356, 1968.
9. 9. Tasaka Y, Inoue Y, Matumoto H, Hirata Y. Changes in plasma glucagon, pancreatic polypeptide and insulin during development of alloxan diabetes mellitus in dog. Endocrinol Jpn 35:399-404, 1988.
10. 10. Gorray KC, Baskin DG, Fujimoto WY. Cytotoxic effects of alloxan treatment in vitro on monolayer cultures of neonatal rat pancreas. Am J Physiol 245:E417-423, 1983.
11. 11. Douglas MI, Rothman L, Katz LD, Shulman RG, Shulman GI. Increased rate of gluconeogenesis in type 2 diabetes mellitus. J Clin Invest 90:1323-1327, 1992.
12. 12. Yamamoto H, Uchigata Y, Okamoto Y. Streptozotocin and alloxan induce DNA strand breaks and poly(ADP-ribose) synthetase in pancreatic islets. Nature 294:284-286, 1981.
13. 13. Turner RC, Holman RR. Insulin use in NIDDM - Rationale based on pathophysiology of disease. Diabetes Care 13:1011-1020, 1990.